Silex Systems (ASX: SLX) — Perfil da empresa, notícias e dados financeiros
Silex Systems develops SILEX laser enrichment technology for uranium isotopes, aiming for a cost-effective and eco-friendly process.
Silex Systems
Silex Systems is a technology research and development company focused on the commercialisation of laser-based isotope separation technology. Headquartered in Australia, the company's core asset is its proprietary laser enrichment process, licensed exclusively to Global Laser Enrichment for application in the nuclear fuel supply chain. Its primary commercial project involves processing depleted uranium tails to produce natural-grade uranium oxide, low-enriched uranium, and high-assay low-enriched uranium for commercial nuclear power reactors. Silex Systems also develops laser isotope separation for producing high-purity silicon-28 for quantum computing processors and medical radioisotopes for targeted cancer therapies.
Resumo
Operações
Produtos e/ou serviços de Silex Systems
- Laser Isotope Separation Licensing: Commercial licensing of proprietary laser isotope separation technology to joint-venture commercial partners for uranium enrichment, supplying enriched uranium fuel components and processing capabilities to the global nuclear energy industry.
- Depleted Uranium Tails Re-enrichment: Commercial re-enrichment of stockpiled depleted uranium tails at a dedicated processing facility in Kentucky, United States, designed to yield up to five million pounds of natural-grade uranium oxide annually for nuclear utilities.
- Low-Enriched Uranium Fuel Processing: Laser enrichment services designed to produce commercial low-enriched uranium and LEU+ fuel containing up to ten percent uranium-235, supplying fuel requirements for conventional large-scale nuclear power reactors and light water utility units.
- High-Assay Low-Enriched Uranium Production: Specialized laser isotope enrichment capabilities producing high-assay low-enriched uranium enriched up to twenty percent uranium-235 to meet fuel demand for next-generation advanced nuclear power reactors and small modular reactor designs.
- Enriched Quantum Silicon Manufacturing: Commercial production and supply of high-purity enriched silicon-28 isotope material, serving as a critical zero-spin substrate required for building silicon-based quantum computing processors, microchips, and quantum computing hardware.
- Medical Radioisotope Enrichment: Development of laser-based isotope separation technology targeting high-value medical radioisotopes, including enriched precursors such as ytterbium-176 used for producing targeted alpha therapy isotopes for targeted cancer treatment applications.
equipe executiva do Silex Systems
- Michael P. GoldsworthyCEO, MD & Executive Director
- Julie E. RussellCFO & Company Secretary
- Geordie GraetzChief Commercial Officer
Últimas notícias sobre a Silex Systems
Comunicados recentes
O que a Silex Systems (SLX) comunicou ao mercado, do mais recente para o mais antigo.
- Becoming a substantial holder
Principais indicadores financeiros
Resultados divulgados pela Silex Systems, em AUD.
- Cap. de mercado
- 984,1 mi
- Receita (TTM)
- 18,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -204.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 13,7 mi | -4,5 mi | -38,6 mi | |
| 6,8 mi | -12,8 mi | -42,6 mi | |
| 6,1 mi | -10,1 mi | -22,7 mi | |
| 6,8 mi | -6,6 mi | -17,4 mi |